432037-57-5 Usage
General Description
The chemical "1-[[[[2-[2-[2-[2-Methoxyethoxy]ethoxy]ethoxy]ethoxy]carbonyl]oxy]methyl]-4-[N'-cyano-N''-[6-[4-chlorophenoxy]hexyl]guanidino]pyridinium chloride" is a complex compound that is composed of multiple functional groups and a pyridinium chloride moiety. It contains a guanidino group, a cyano group, multiple ether linkages and a carbonyl group, as well as a pyridinium cation. The compound likely has a variety of potential uses due to the presence of these functional groups, such as in drug development, materials science, or biotechnology. However, due to its complex structure, it may also have potential hazards, and caution should be taken when handling and using this chemical.
Check Digit Verification of cas no
The CAS Registry Mumber 432037-57-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,3,2,0,3 and 7 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 432037-57:
(8*4)+(7*3)+(6*2)+(5*0)+(4*3)+(3*7)+(2*5)+(1*7)=115
115 % 10 = 5
So 432037-57-5 is a valid CAS Registry Number.
432037-57-5Relevant articles and documents
Compositions and Methods for Effecting NAD+ Levels Using A Nicotinamide Phosphoribosyl Tranferase Inhibitor
-
, (2009/07/10)
The present invention relates to methods for decreasing cellular DNA repair in a target patient; decreasing cellular NAD+ biosynthesis in a target patient; increasing efficiency of radiation therapy in a target patient; modulating nicotinamide phosphoribosyl transferase activity in a patient; or sensitizing a patient to a DNA damaging therapy. The invention relates to methods for treating a patient who received a toxic dose of an nicotinamide phosphoribosyl transferase inhibitor. The invention also relates to pharmaceutical compositions comprising a physiologically acceptable carrier; an effective amount of a NMPRT inhibitor; and nicotinic acid. The invention also relates to methods for treating a patient diagnosed with or suspected to have a cancer deficient in nicotinic acid pathway.
